Research article · 15 Jul 2025
Conference abstractPublished 2018
Efficacy and safety of clobazam in a pediatric refractory epilepsy population less than two years of age
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Aim: To describe our experience with the efficacy and safety of clobazam in refractory epilepsy in a large population of children less than two years of age. Methods: We retrospectively reviewed all patients between 0 and 2 years of age at Boston Children’s Hospital from October 2011 to December 2016. We included patients who were treated with clobazam for refractory epilepsy, and who had a followup visit at least one month after starting clobazam. Response to clobazam was defined as >50% reduction in seizure frequency at the time of last follow-up visit as compared to baseline. Results: 155 patients received clobazam, of which 116 [median age 12 months, IQR (p25-p75) 8-16 months] had full followup data ≥1 month after starting clobazam. Median follow-up age was 14 months [IQR (p25-p75) 9-18 months]. At the time of clobazam initiation, 31/116 (27%) patients were on one antiepileptic drug (AED), 52/116 (45%) patients were on two AEDs, and 26/116 (22%) patients were on 3 or more AEDs. 7/116 (6%) patients received clobazam monotherapy. Overall response rate was 33% (38/116) with a median seizure reduction of 75%. 18 (16%) patients had ≤50% reduction, 14 (12%) had no change and 16 (14%) had worsening of seizure frequency. 30 (26%) patients became seizure free. 8 (7%) patients discontinued clobazam. Conclusions: Clobazam is both well tolerated and effective in reducing seizure frequency in pediatric patients less than two years of age with refractory epilepsy
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Neurology and Neuroscience.
Research article · 15 Jul 2025
Diffuse Intrinsic Pontine Glioma: Unusually Long Survival of 28 Patients (From 3 Years to Over 29 Years) in Phase 2 Studies with Antineoplastons A10 and AS2-1
Short communication · 24 Jun 2025
The Role of High-Pressure Balloon Angioplasty in Treating Intracranial Atherosclerosis
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Neurology and Neuroscience
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Ersida Buraniqi”
- BylineArticles whose byline prints “Xiaofan Wang”
- BylineArticles whose byline prints “Fatemeh Mohammadpour Touserkani”
- BylineArticles whose byline prints “Kush Kapur”
- BylineArticles whose byline prints “Tobias Loddenkemper”
